U.S. overdose deaths dropped during 2018 for the first time in nearly two decades, the CDC said, in a sign that a nationwide epidemic of drug-related deaths is abating.
GlaxoSmithKline Plc’s cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said.
Opioid use has reached crisis proportions not only in the United States but also in Canada and some European countries, as prescription opioid painkillers have become much more common, the OECD club of wealthy nations said.
More U.S. adults are dying from heart failure today than a decade ago, and the sharpest rise in mortality is happening among middle-aged and younger adults, a new study suggests.
Novartis raised the company’s 2019 profit target, striking an upbeat tone over a legal fight with peer and partner Amgen and on the safety of a key gene therapy that could win approval in May 2019.
Janssen’s Invokana became the only medicine in nearly 20 years and the first diabetes medicine ever to demonstrate a reduction in progression to end-stage renal failure in T2D patients with CKD.
The Philippine Department of Justice has found probable cause to indict officials from French drugmaker Sanofi and former and current Philippine health officials over 10 deaths the department said were linked to use of a dengue vaccine.
Merck & Co. Inc. said the combination of the drugmaker’s cancer immunotherapy Keytruda with Pfizer Inc.’s Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with the chemotherapy drug Sutent.
Researchers are reporting a link between doctor-targeted marketing of opioid products and the increase in U.S. deaths from overdoses.
The year 2018 saw a number of significant triumphs in the biopharma industry – increased numbers of drug approvals and near record-shattering IPOs, but the industry also saw its share of blemishes and black eyes from various corners of the globe.